ArticleLipids in health and disease2026
Abnormal lipid profile in the context of liver steatosis measured by transient elastography: experiences from an outpatient endocrine clinic.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDyslipidaemia is a recognised risk factor for cardiovascular diseases which remain the leading cause of death worldwide. There is a knowledge gap whether the prevalence/pattern of dyslipidaemia depends on the aetiology of the liver disease.
objectiveTo evaluate the association between dyslipidaemia and chronic liver diseases.
methodsA cross-sectional study included adults aged ≥ 18 years, who attended outpatient Endocrine clinic between January 2023 and April 2025. Patients who underwent both transient elastography and lipid profile measurement were included in the analysis. Data on participants’ demographics, history of glucose intolerance, statin treatment, liver function tests, and non-invasive liver fibrosis markers were recorded. Descriptive statistics and binary logistic regression were performed to study the associations.
resultsThe study included 329 participants (aged 47 ± 14 years, 53.8% males), of whom 68.4% had steatotic liver disease (SLD) and 23.1% had viral hepatitis. Dyslipidaemia was associated with higher mean of controlled attenuation parameter (CAP) (297.4 ± 49.8 vs. 267.2 ± 56.9, P = 0.002) and higher prevalence of liver steatosis (91.7% vs. 72.1%, P < 0.001). 90.9% of participants with dyslipidaemia had SLD, whereas only 72.1% of those with optimal lipid profile had SLD (P < 0.001). In the univariable (bivariate) analysis, CAP was significantly associated with dyslipidaemia (OR = 1.01, 95%CI = 1.01–1.02, P < 0.001). The final multivariable logistic regression retained CAP as the predictor of dyslipidaemia (aOR = 1.02, 95%CI = 1.01–1.04, P = 0.001).
conclusionsThe findings suggest that dyslipidaemia is common among individuals with steatotic liver disease and is associated with hepatic steatosis quantified by CAP, rather than fibrosis. These findings highlight the importance of accessible, non-invasive diagnostic approaches in strengthening preventive and management approaches in routine clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.